공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

복합부위 통증 증후군(CRPS) 시장 : 인사이트, 역학, 예측(-2030년)

Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology and Market Forecast-2030

리서치사 DelveInsight Business Research LLP
발행일 On Demand Report 상품 코드 980951
페이지 정보 영문 201 Pages
가격
US $ 6,950 ₩ 8,062,000 PDF (Single User License)
US $ 13,900 ₩ 16,125,000 PDF (Site License)
US $ 20,850 ₩ 24,188,000 PDF (Global License)


복합부위 통증 증후군(CRPS) 시장 : 인사이트, 역학, 예측(-2030년) Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology and Market Forecast-2030
발행일 : On Demand Report 페이지 정보 : 영문 201 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

주요 7개국(미국, 유럽 5개국(독일, 스페인, 이탈리아, 프랑스 및 영국), 일본)의 복합부위 통증 증후군(CRPS) 시장 규모는 2017-2030년간 변화할 것으로 예상됩니다. 시장 규모는 2017년 6,500만 달러에 달했으며, 조사 기간중(2017-2030년)에 증가할 전망입니다. CRPS 최대 시장 규모는 미국인 것으로 추정되며, 독일, 프랑스, 영국이 그 뒤를 잇고 있습니다.

복합부위 통증 증후군(CRPS)은 가장 심한 만성 통증 질환 중 하나이며, 피부병변이 없는 자발적인 국소통이 서서히 악화되는 것을 특징으로 하고 있습니다. 통증은 시간과 중증도에 비례하지 않고, 피부 변화, 자율신경기능 장애, 감각이나 운동 이상, 영양상태 변화 등 중증도에 따라 변화하는 증상을 수반하고 있습니다. CRPS는 대규모 외상, 수술, 또는 경도의 외상 후에 발병하는 경우가 있으며, 자기한정적인 경도 증상에서부터 만성질환에 이르기까지 변화가 많은 경과를 밟으며 진행됩니다.

주요 7개국(미국, 유럽 5개국(독일, 스페인, 이탈리아, 프랑스 및 영국), 일본)의 복합부위 통증 증후군(CRPS: Complex Regional Pain Syndrome) 시장에 대해 조사했으며, 역학, 시장 규모와 예측, 성장요인 및 과제, 치료법·국가별 시장 분석, 경쟁 구도, 주요 기업 제품 등의 정보를 제공합니다.

목차

제1장 주요 인사이트

제2장 개요

제3장 SWOT 분석

제4장 역학과 시장 예측

제5장 시장 개요

  • 전체 시장 점유율(2017년)
  • 전체 시장 점유율(2030년)

제6장 질환의 배경과 개요

  • 서론
  • 증상
  • 원인
  • CRPS의 결과
  • 임상 프리젠테이션
  • CRPS의 자연스러운 경과
  • 분류
  • 병태생리학
  • 진단
    • 조사
    • 영상 기술
    • 비침습적 영상 기술
    • 서모그래피
    • 발한 기능 검사
    • 신경생리학적 검사
    • 검사
    • 감별 진단
  • CRPS 진단 가이드라인
    • Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 4th Edition - the USA
    • UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults
    • 일본의 CRPS 진단 기준

제7장 역학과 환자 인구

  • 주요 조사 결과
  • 전제조건과 이론적 근거
  • 역학 시나리오 : 주요 7개국
    • CRPS의 총유병률
    • CRPS 진단 유병률 합계
    • 성별 CRPS 진단 유병률
    • 연령별 CRPS 연령별 진단 유병률
    • 타입별 CRPS 진단 유병률
    • 중증도별 CRPS 진단 유병률
    • 치료된 CRPS 증례
  • 미국의 역학
  • 유럽의 5개국 역학
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본

제8장 CRPS 치료와 관리

  • 치료 가이드라인
    • Practical Diagnostic and Treatment Guidelines, 4th Edition - the USA
    • UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults

제9장 충족되지 않은 욕구

제10장 환자 여정

제11장 CRPS 임상시험의 주요 엔드포인트

제12장 새로운 치료법

  • 경쟁 구도
  • Soticlestat(TAK-935/OV935) : Ovid Therapeutics/Takeda
    • 제품 개요
    • 기타 개발 활동
    • 임상 개발
  • BHV-5000: AstraZeneca/Biohaven Pharmaceutical

제13장 CRPS : 주요 7개국 시장 분석

  • 주요 조사 결과
  • 시장 전망 : 주요 7개국
  • 주요 7개국 시장 규모
    • 주요 7개국 CRPS 전체 시장 규모
    • 주요 7개국 치료법별 CRPS 전체 시장 규모
  • 미국 시장 규모
  • 유럽 5개국 시장 규모
  • 독일 시장 규모
  • 프랑스 시장 규모
  • 이탈리아 시장 규모
  • 스페인 시장 규모
  • 영국 시장 규모
  • 일본 시장 규모

제14장 시장 접근과 상환

제15장 시장 성장요인

제16장 시장 장벽

제17장 부록

  • 참고 문헌
  • 보고서의 조사 방법

제18장 DelveInsight의 서비스 내용

제19장 면책사항

제20장 DelveInsight에 대해

LSH 21.01.25

List of Tables

  • Table 1 Summary of CRPS, Market, Epidemiology, and Key Events (2017-2030)
  • Table 2 Comparison of CRPS Types
  • Table 3 Common characteristics of CRPS
  • Table 4 Stages of CRPS
  • Table 5 IASP clinical diagnostic criteria for CRPS - Budapest Criteria (2012)
  • Table 6 Difference between CRPS Types
  • Table 7 Possible mechanisms involved in complex regional pain syndrome
  • Table 8 Summary of pathophysiologic mechanisms that may contribute to CRPS
  • Table 9 Differential Diagnosis
  • Table 10 Technical investigations helpful to exclude a differential diagnosis
  • Table 11 Differential Diagnosis
  • Table 12 Levels of evidence
  • Table 13 Original International Association for the Study of Pain (Orlando) diagnostic criteria for complex regional pain syndrome
  • Table 14 Factors (and factor loadings) resulting from principal components factor analysis of diagnostic and associated signs and symptoms of CRPS
  • Table 15 Clinical diagnostic criteria for CRPS
  • Table 16 Summary of sensitivity and specificity of the clinical and research criteria
  • Table 17 Diagnosis of CRPS - Recommendations
  • Table 18 Referral - Recommendations
  • Table 19 Surgical practice - Diagnostic Recommendations
  • Table 20 Diagnosis of CRPS in emergency medicine - Recommendations
  • Table 21 The Veldman criteria
  • Table 22 Factors (and factor loadings) resulting from factor analysis of CRPS-related signs/symptoms
  • Table 23 Japanese CRPS diagnostic criteria for clinical purposes
  • Table 24 Total Prevalent Cases of CRPS in the 7MM (2017-2030)
  • Table 25 Total Diagnosed Prevalent cases of CRPS in the 7MM (2017-2030)
  • Table 26 Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017-2030)
  • Table 27 Age-specific Prevalent Cases of CRPS in the 7MM (2017-2030)
  • Table 28 Type-specific Diagnosed Prevalent Cases of CRPS in 7MM (2017-2030)
  • Table 29 Severity-Specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017-2030)
  • Table 30 Total Treated cases of CRPS in the 7MM (2017-2030)
  • Table 31 Total Prevalent Cases of CRPS in the United States (2017-2030)
  • Table 32 Total Diagnosed Prevalent cases of CRPS in the United States (2017-2030)
  • Table 33 Gender-specific Diagnosed Prevalent Cases of CRPS in the United States (2017-2030)
  • Table 34 Age-specific Prevalent Cases of CRPS in the United States (2017-2030)
  • Table 35 Type-specific Diagnosed Prevalent Cases of CRPS in the United States (2017-2030)
  • Table 36 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United States (2017-2030)
  • Table 37 Total Treated cases of CRPS in the United States (2017-2030)
  • Table 38 Total Prevalent Cases of CRPS in Germany (2017-2030)
  • Table 39 Total Diagnosed Prevalent cases of CRPS in Germany (2017-2030)
  • Table 40 Gender-specific Diagnosed Prevalent Cases of CRPS in Germany (2017-2030)
  • Table 41 Age-specific Prevalent Cases of CRPS in Germany (2017-2030)
  • Table 42 Type-specific Diagnosed Prevalent Cases of CRPS in Germany (2017-2030)
  • Table 43 Severity-Specific Diagnosed Prevalent Cases of CRPS in Germany (2017-2030)
  • Table 44 Total Treated cases of CRPS in Germany (2017-2030)
  • Table 45 Total Prevalent Cases of CRPS in France (2017-2030)
  • Table 46 Total Diagnosed Prevalent cases of CRPS in France (2017-2030)
  • Table 47 Gender-specific Diagnosed Prevalent Cases of CRPS in France (2017-2030)
  • Table 48 Age-specific Prevalent Cases of CRPS in France (2017-2030)
  • Table 49 Type-specific Diagnosed Prevalent Cases of CRPS in France (2017-2030)
  • Table 50 Severity-Specific Diagnosed Prevalent Cases of CRPS in France (2017-2030)
  • Table 51 Total Treated cases of CRPS in France (2017-2030)
  • Table 52 Total Prevalent Cases of CRPS in Italy (2017-2030)
  • Table 53 Total Diagnosed Prevalent cases of CRPS in Italy (2017-2030)
  • Table 54 Gender-specific Diagnosed Prevalent Cases of CRPS in Italy (2017-2030)
  • Table 55 Age-specific Prevalent Cases of CRPS in Italy (2017-2030)
  • Table 56 Type-specific Diagnosed Prevalent Cases of CRPS in Italy (2017-2030)
  • Table 57 Severity-Specific Diagnosed Prevalent Cases of CRPS in Italy (2017-2030)
  • Table 58 Total Treated cases of CRPS in Italy (2017-2030)
  • Table 59 Total Prevalent Cases of CRPS in Spain (2017-2030)
  • Table 60 Total Diagnosed Prevalent cases of CRPS in Spain (2017-2030)
  • Table 61 Gender-specific Diagnosed Prevalent Cases of CRPS in Spain (2017-2030)
  • Table 62 Age-specific Prevalent Cases of CRPS in Spain (2017-2030)
  • Table 63 Type-specific Diagnosed Prevalent Cases of CRPS in Spain (2017-2030)
  • Table 64 Severity-Specific Diagnosed Prevalent Cases of CRPS in Spain (2017-2030)
  • Table 65 Total Treated cases of CRPS in Spain (2017-2030)
  • Table 66 Total Prevalent Cases of CRPS in the United Kingdom (2017-2030)
  • Table 67 Total Diagnosed Prevalent cases of CRPS in the United Kingdom (2017-2030)
  • Table 68 Gender-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017-2030)
  • Table 69 Age-specific Prevalent Cases of CRPS in the United Kingdom (2017-2030)
  • Table 70 Type-specific Diagnosed Prevalent Cases of CRPS in the United kingdom (2017-2030)
  • Table 71 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017-2030)
  • Table 72 Total Treated cases of CRPS in the United Kingdom (2017-2030)
  • Table 73 Total Prevalent Cases of CRPS in Japan (2017-2030)
  • Table 74 Total Diagnosed Prevalent cases of CRPS in Japan (2017-2030)
  • Table 75 Gender-specific Diagnosed Prevalent Cases of CRPS in Japan (2017-2030)
  • Table 76 Age-specific Prevalent Cases of CRPS in Japan (2017-2030)
  • Table 77 Type-specific Diagnosed Prevalent Cases of CRPS in Japan (2017-2030)
  • Table 78 Severity-Specific Diagnosed Prevalent Cases of CRPS in Japan (2017-2030)
  • Table 79 Total Treated cases of CRPS in Japan (2017-2030)
  • Table 80 Pharmacotherapy guide
  • Table 81 Management of suspected or confirmed CRPS - Recommendations
  • Table 82 Therapeutic approaches
  • Table 83 Yellow Flags
  • Table 84 Examples of CRPS-specific rehabilitation techniques
  • Table 85 Occupational therapy and physiotherapy- Recommendations
  • Table 86 Surgical practice - Management Recommendations
  • Table 87 Surgery to amputate the CRPS-affected limb - Recommendations
  • Table 88 Management and referral of CRPS in emergency medicine - Recommendations
  • Table 89 Management of CRPS in pain clinics
  • Table 90 Management of CRPS in pain clinics-referral
  • Table 91 Management of patients with CRPS and complex needs
  • Table 92 Long-term support in CRPS
  • Table 93 Key Cross Competition of Emerging Drugs
  • Table 94 Soticlestat (TAK-935/OV935), Clinical Trial Description, 2020
  • Table 95 List of Few Discontinued Drugs for CRPS
  • Table 96 7MM Market Size of CRPS, in USD Million (2017-2030)
  • Table 97 7MM Market Size of CRPS by Therapies, in USD Million (2017-2030)
  • Table 98 United States Market Size of CRPS by Therapies, in USD Million (2017-2030)
  • Table 99 Germany Market Size of CRPS by Therapies, in USD Million (2017-2030)
  • Table 100 France Market Size of CRPS by Therapies, in USD Million (2017-2030)
  • Table 101 Italy Market Size of CRPS by Therapies, in USD Million (2017-2030)
  • Table 102 Spain Market Size of CRPS by Therapies, in USD Million (2017-2030)
  • Table 103 United Kingdom Market Size of CRPS by Therapies, in USD Million (2017-2030)
  • Table 104 Japan Market Size of CRPS by Therapies, in USD Million (2017-2030)

List of Figures

  • Figure 1 CRPS SWOT Analysis
  • Figure 2 Complex regional pain syndrome - CRPS
  • Figure 3 Typical features of a patient with CRPS
  • Figure 4 Causes of CRPS
  • Figure 5 Model for the development of complex regional pain syndrome (CRPS) from nerve injury
  • Figure 6 Speculative model of interacting mechanisms involved in the development of CRPS
  • Figure 7 Total Prevalent Cases of CRPS in the 7MM (2017-2030)
  • Figure 8 Total Diagnosed Prevalent cases of CRPS in the 7MM (2017-2030)
  • Figure 9 Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017-2030)
  • Figure 10 Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017-2030)
  • Figure 11 Type-specific Diagnosed Prevalent Cases of CRPS in 7MM (2017-2030)
  • Figure 12 Severity-Specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017-2030)
  • Figure 13 Treated cases of CRPS in the 7MM (2017-2030)
  • Figure 14 Total Prevalent Cases of CRPS in the United States (2017-2030)
  • Figure 15 Total Diagnosed Prevalent cases of CRPS in the United States (2017-2030)
  • Figure 16 Gender-specific Diagnosed Prevalent Cases of CRPS in the United States (2017-2030)
  • Figure 17 Age-specific Diagnosed Prevalent Cases of CRPS in the United States (2017-2030)
  • Figure 18 Type-specific Diagnosed Prevalent Cases of CRPS in the United States (2017-2030)
  • Figure 19 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United States (2017-2030)
  • Figure 20 Treated cases of CRPS in the United States (2017-2030)
  • Figure 21 Total Prevalent Cases of CRPS in Germany (2017-2030)
  • Figure 22 Total Diagnosed Prevalent cases of CRPS in Germany (2017-2030)
  • Figure 23 Gender-specific Diagnosed Prevalent Cases of CRPS in Germany (2017-2030)
  • Figure 24 Age-specific Diagnosed Prevalent Cases of CRPS in Germany (2017-2030)
  • Figure 25 Type-specific Diagnosed Prevalent Cases of CRPS in Germany (2017-2030)
  • Figure 26 Severity-Specific Diagnosed Prevalent Cases of CRPS in Germany (2017-2030)
  • Figure 27 Treated cases of CRPS in Germany (2017-2030)
  • Figure 28 Total Prevalent Cases of CRPS in France (2017-2030)
  • Figure 29 Total Diagnosed Prevalent cases of CRPS in France (2017-2030)
  • Figure 30 Gender-specific Diagnosed Prevalent Cases of CRPS in France (2017-2030)
  • Figure 31 Age-specific Diagnosed Prevalent Cases of CRPS in France (2017-2030)
  • Figure 32 Type-specific Diagnosed Prevalent Cases of CRPS in France (2017-2030)
  • Figure 33 Severity-Specific Diagnosed Prevalent Cases of CRPS in France (2017-2030)
  • Figure 34 Treated cases of CRPS in France (2017-2030)
  • Figure 35 Total Prevalent Cases of CRPS in Italy (2017-2030)
  • Figure 36 Total Diagnosed Prevalent cases of CRPS in Italy (2017-2030)
  • Figure 37 Gender-specific Diagnosed Prevalent Cases of CRPS in Italy (2017-2030)
  • Figure 38 Age-specific Diagnosed Prevalent Cases of CRPS in Italy (2017-2030)
  • Figure 39 Type-specific Diagnosed Prevalent Cases of CRPS in Italy (2017-2030)
  • Figure 40 Severity-Specific Diagnosed Prevalent Cases of CRPS in Italy (2017-2030)
  • Figure 41 Treated cases of CRPS in Italy (2017-2030)
  • Figure 42 Total Prevalent Cases of CRPS in Spain (2017-2030)
  • Figure 43 Total Diagnosed Prevalent cases of CRPS in Spain (2017-2030)
  • Figure 44 Gender-specific Diagnosed Prevalent Cases of CRPS in Spain (2017-2030)
  • Figure 45 Age-specific Diagnosed Prevalent Cases of CRPS in Spain (2017-2030)
  • Figure 46 Type-specific Diagnosed Prevalent Cases of CRPS in Spain (2017-2030)
  • Figure 47 Severity-Specific Diagnosed Prevalent Cases of CRPS in Spain (2017-2030)
  • Figure 48 Treated cases of CRPS in Spain (2017-2030)
  • Figure 49 Total Prevalent Cases of CRPS in the United Kingdom (2017-2030)
  • Figure 50 Total Diagnosed Prevalent cases of CRPS in the United Kingdom (2017-2030)
  • Figure 51 Gender-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017-2030)
  • Figure 52 Age-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017-2030)
  • Figure 53 Type-specific Diagnosed Prevalent Cases of CRPS in the United kingdom (2017-2030)
  • Figure 54 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017-2030)
  • Figure 55 Treated cases of CRPS in the United Kingdom (2017-2030)
  • Figure 56 Total Prevalent Cases of CRPS in Japan (2017-2030)
  • Figure 57 Total Diagnosed Prevalent cases of CRPS in Japan (2017-2030)
  • Figure 58 Gender-specific Diagnosed Prevalent Cases of CRPS in Japan (2017-2030)
  • Figure 59 Age-specific Diagnosed Prevalent Cases of CRPS in Japan (2017-2030)
  • Figure 60 Type-specific Diagnosed Prevalent Cases of CRPS in Japan (2017-2030)
  • Figure 61 Severity-Specific Diagnosed Prevalent Cases of CRPS in Japan (2017-2030)
  • Figure 62 Treated cases of CRPS in Japan (2017-2030)
  • Figure 63 Treatment algorithm
  • Figure 64 Four pillars of treatment for CRPS - an integrated interdisciplinary approach
  • Figure 65 Pathophysiology and mechanism-based treatment options in CRPS
  • Figure 66 CRPS rehabilitation algorithm for occupational therapists and physiotherapists
  • Figure 67 Unmet Needs of CRPS
  • Figure 68 Market Size of CRPS in the 7MM, in USD Million (2017-2030)
  • Figure 69 Market Size of CRPS in the 7MM by Therapies, in USD Million (2017-2030)
  • Figure 70 Market Size of CRPS in the United States by Therapy, in USD Million (2017-2030)
  • Figure 71 Market Size of CRPS in Germany by Therapies, in USD Million (2017-2030)
  • Figure 72 Market Size of CRPS in France by therapies, in USD Million (2017-2030)
  • Figure 73 Market Size of CRPS in Italy by Therapies, in USD Million (2017-2030)
  • Figure 74 Market Size of CRPS in Spain by therapies, in USD Million (2017-2030)
  • Figure 75 Market Size of CRPS in the United Kingdom by Therapies, in USD Million (2017-2030)
  • Figure 76 Market Size of CRPS in Japan by Therapy, in USD Million (2017-2030)
  • Figure 77 Market Drivers
  • Figure 78 Market Barriers

DelveInsight's 'Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the CRPS, historical and forecasted epidemiology as well as the CRPS market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The CRPS market report provides current treatment practices, emerging drugs, CRPS market share of the individual therapies, current and forecasted CRPS market size from 2017 to 2030 segmented by seven major markets. The Report also covers current CRPS treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Complex Regional Pain Syndrome (CRPS) Disease Understanding and Treatment Algorithm

Complex Regional Pain Syndrome Overview

Complex regional pain syndrome (CRPS) is one of the most challenging chronic pain condition that is characterized by progressively worsening spontaneous regional pain without dermatomal distribution. The pain experienced is out of proportion in time and severity to the inciting event and accompanied by symptoms that vary in severity including skin changes, autonomic dysfunction, abnormal sensory and motor changes, and trophic changes. CRPS may develop after major trauma, surgery, or minor injury, and progresses with a variable course that ranges from self-limiting, mild symptomatology to chronic disease. In many cases, disease progression is debilitating and severely limits patients' quality of life, creating a tremendous burden on patients and their families. Over time, CRPS has been defined and redefined. CRPS develops after an inciting noxious stimulus to an affected limb. There is little agreement with regards to the etiology, symptoms, clinical presentation, diagnosis, or treatment of CRPS.

In order to bring some uniformity to this problem, the International Association for the Study of Pain (IASP) in 1994 introduced the term CRPS to describe a wide variety of post-traumatic neuropathic pain conditions of the limbs. There are two types of CRPS, Type I occurs after an illness or injury that did not directly damage a nerve in the affected area, and Type II follows a distinct nerve injury. Although the triggers vary, both types of CRPS have the same symptoms and go through the same three stages of the disease. CRPS used to be known as reflex sympathetic dystrophy (RSD) (Type I) and causalgia (Type II). Type I comprises about 90 percent of all cases of CRPS. Patients typically progress through three stages -Stage I or acute stage (may last up to 3 months), Stage II or Dystrophic stage (can last 3-12 months), Stage III and atrophic stage (occurs after 1 year). There are no objective diagnostic tests for CRPS. Since, its pathophysiologic basis of CRPS is not fully understood, mechanism-based diagnosis is not yet feasible. Therefore, the diagnosis of CRPS is based solely on clinical signs and symptoms. The actual diagnosis of CRPS is made solely based on history and physical examination to determine whether a patient meets CRPS diagnostic criteria (often called the Budapest criteria). Other than this, objective testing (thermography, triple-phase bone scan, quantitative sudomotor axon reflex test, or a trial sympathetic ganglion block) may be used to support a clinical diagnosis.

CRPS Diagnosis

There are no objective diagnostic tests for CRPS. Since, its pathophysiologic basis of CRPS is not fully understood, mechanism-based diagnosis is not yet feasible. Therefore, the diagnosis of CRPS is based solely on clinical signs and symptoms. The actual diagnosis of CRPS is made solely based on history and physical examination to determine whether a patient meets CRPS diagnostic criteria (often called the Budapest criteria). Other than this, objective testing (thermography, triple-phase bone scan, quantitative sudomotor axon reflex test, or a trial sympathetic ganglion block) may be used to support a clinical diagnosis.

CRPS Treatment

Given these obstacles to diagnosis, treatment, and research, Interdisciplinary approach is currently practiced widely for the management of CRPS which define the market scenario. Different interventional and non-interventional treatment modalities are applied empirically in a timely manner to facilitate reanimation of the affected extremity. Current treatment for CRPS includes non-surgical methods like medications (Pain reliever, Antidepressants and anticonvulsants, Corticosteroids, and Sympathetic nerve-blocking medication), Biofeedback, and therapy.

CRPS Epidemiology

The CRPS epidemiology division provides the insights about historical and current CRPS patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2017, the total prevalent case of CRPS was 310,489 in the 7MM which are expected to grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted CRPS epidemiology [segmented as Total prevalent cases of CRPS, Total diagnosed prevalent cases of CRPS, Gender-specific diagnosed prevalent cases of CRPS, Age-specific diagnosed prevalent cases of CRPS, Type-specific diagnosed prevalent cases of CRPS, Severity-specific diagnosed prevalent cases of CRPS, and Total Treated Cases of CRPS scenario of CRPS in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

Country Wise- CRPS Epidemiology

  • In the United States, the total number of prevalent cases of CRPS was 219,317 cases in the year 2017 which are expected to grow during the study period, i.e., 2017-2030.
  • In the year 2017, the total prevalent cases of CRPS were 84,850 cases in EU-5 which are expected to grow during the study period, i.e., 2017-2030.
  • In Japan, the total number of prevalent cases of CRPS was 6,323 cases in the year 2017 which are expected to grow during the study period, i.e., 2017-2030.
  • In the 7MM, the total gender-specific diagnosed prevalent cases of CRPS were 47,699 for males and 102,987 for females in the year 2017.
  • In 7MM, the highest number (~87% of CRPS cases) of type-specific diagnosed prevalent cases recorded in 2017 for CRPS I, i.e., 131,278 cases.
  • This condition affects people of all ages. Around 3/4th cases of CRPS are reported in the people age group of 20-60 years of age. In the 7MM, the age-specific diagnosed prevalent cases for age-group 40-59 years were 72,247 in 2017.

CRPS Drug Chapters

Drug chapter segment of the CRPS report encloses the detailed analysis of CRPS developmental stage pipeline drugs. It also helps to understand the CRPS clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

CRPS Emerging Drugs

Soticlestat (TAK-935/OV935): Ovid Therapeutics/Takeda

Soticlestat, also known as OV935 or TAK-935 is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. Soticlestat has completed (October 2020) Phase II (NCT03990649; EudraCT 2018-004750-21) of clinical trial in patients with CRPS.

BHV-5000: AstraZeneca/Biohaven Pharmaceutical

Biohaven Pharmaceutical's, BHV-5000 is an orally available, first-in-class, low-trapping, NMDA receptor antagonist. It is being developed for the treatment of neuropsychiatric disorders such as CRPS, Rett Syndrome and Major Depression. The company has already completed a Phase I trial in 2018 to evaluate its pharmacokinetic properties. This drug was reported to be well-tolerated.

Note: Detailed emerging therapies assessment will be provided in the final report.

CRPS Market Outlook

Key Findings

The CRPS market size in the 7MM is expected to change during the study period 2017-2030. The therapeutic market of CRPS in the seven major markets was USD 65 million in 2017 which is expected to increase during study period (2017-2030). According to the estimates, the highest market size of CRPS is found in the United States followed by Germany, France, and the UK.

The United States Market Outlook

In 2017, the total market size of CRPS therapies was USD 55 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of CRPS therapies was USD 9.5 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of CRPS therapies in Japan was USD 0.7 million in 2017 which is expected to increase in the study period (2017-2030).

CRPS Pipeline Development Activities

The drugs which are in pipeline include:

1. Soticlestat (TAK-935/OV935): Ovid Therapeutics/Takeda

2. BHV-5000: AstraZeneca/Biohaven Pharmaceutical

Note: Detailed emerging therapies assessment will be provided in the final report.

CRPS Drugs Uptake

There is dearth of US FDA and EMA approved therapies for CRPS and current market is mainly dominated by off-label therapies such as Non-opioid analgesics, Opioid analgesics, Co-analgesics, Local treatment, and others. In the absence of approved therapies, Opioid analgesics which are mainly reserved for Moderate-to-severe or refractory pool, grabbed the highest market share in 2017, followed by Co-analgesics among the off-label therapies. In comparison to all the therapies (off-label and forecasted therapies), Soticlestat (TAK-935) will going to have a major influence on market size CRPS in the 7MM, if approved.

Access and Reimbursement Scenario in CRPS Therapies

  • CRPS is a rare disease, and one of the most crippling persistent conditions. A few factors which act as barriers to adequate care apart from insufficient insurance coverage for pain management services, are scarcities of medical and behavioral pain management experts, underestimation of patients' reports of pain, vain working medication supply frameworks, and dearth of research on CRPS management approaches.

KOL-Views

To keep up with current market trends, we take KOLs and SME's opinion working in CRPS domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or CRPS market trend. This will support the clients in potential upcoming novel treatment by identifying the over CRPS scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the CRPS Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of CRPS, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the CRPS epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for CRPS is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of CRPS market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global CRPS market.

Report Highlights:

  • In the coming years, CRPS market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence CRPS R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for CRPS. Launch of emerging therapies, will significantly impact the CRPS market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CRPS.
  • Our in-depth analysis of the pipeline assets across different stages of development different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the over CRPS scenario of the research and development activities.

CRPS Report Insights

  • Patient Population
  • Therapeutic Approaches
  • CRPS Pipeline Analysis
  • CRPS Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

CRPS Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • CRPS Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

CRPS Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the CRPS Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the CRPS total market size as well as market size by therapies across the 7MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest CRPS market size during the study period (2017-2030)?
  • At what CAGR, the CRPS market is expected to grow in the 7MM during the study period (2017-2030)?
  • What would be the CRPS market outlook across the 7MM during the study period (2017-2030)?
  • What would be the CRPS market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • CRPS patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the CRPS market?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the CRPS?
  • What is the historical CRPS patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of CRPS in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CRPS?
  • Out of CRPS the 7MM countries, which country would have the highest prevalent population of CRPS during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of CRPS?

Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of CRPS?
  • What are the current treatment guidelines for the treatment of CRPS in the US, Europe and Japan?
  • How many companies are developing therapies for the treatment of CRPS?
  • How many therapies are developed by each company for the treatment of CRPS?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of CRPS?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CRPS therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for CRPS and their status?
  • What are the key designations that have been granted for the emerging therapies for CRPS?
  • What is the global historical and forecasted market of CRPS?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the CRPS market.
  • To understand the future market competition in the CRPS market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for CRPS in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for CRPS market.
  • To understand the future market competition in the CRPS market.

Table of Contents

1. Key Insights

2. Executive Summary of Complex Regional Pain Syndrome (CRPS)

3. SWOT Analysis

4. Epidemiology and Market Forecast Flow

5. Complex Regional Pain Syndrome (CRPS): Market Overview at a Glance

  • 5.1. Total Market Share (%) Distribution of CRPS in 2017
  • 5.2. Total Market Share (%) Distribution of CRPS in 2030

6. Complex Regional Pain Syndrome (CRPS): Disease Background and Overview

  • 6.1. Introduction
  • 6.2. Symptoms
  • 6.3. Causes
  • 6.4. Outcomes of CRPS
  • 6.5. Clinical presentations
  • 6.6. Natural course of CRPS
  • 6.7. Classification
  • 6.8. Pathophysiology
  • 6.9. Diagnosis
    • 6.9.1. Investigations
    • 6.9.2. Imaging Techniques
    • 6.9.3. Non-invasive imaging techniques
    • 6.9.4. Thermography
    • 6.9.5. Sudomotor Function Tests
    • 6.9.6. Neurophysiological Tests
    • 6.9.7. Examination
    • 6.9.8. Differential diagnosis
  • 6.10. Diagnostic Guidelines for CRPS
    • 6.10.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 4th Edition - the USA
    • 6.10.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults
    • 6.10.3. Japanese CRPS diagnostic criteria

7. Epidemiology and Patient Population

  • 7.1. Key Findings
  • 7.2. Assumptions and Rationale
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Total Prevalent Cases of CRPS in the 7MM
    • 7.3.2. Total Diagnosed Prevalent cases of CRPS in the 7MM
    • 7.3.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM
    • 7.3.4. Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM
    • 7.3.5. Type-specific Diagnosed Prevalent Cases of CRPS in 7MM
    • 7.3.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in the 7MM
    • 7.3.7. Treated cases of CRPS in the 7MM
  • 7.4. The United States Epidemiology
    • 7.4.1. Total Prevalent Cases of CRPS in the United States
    • 7.4.2. Total Diagnosed Prevalent cases of CRPS in the United States
    • 7.4.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the United States
    • 7.4.4. Age-specific Diagnosed Prevalent Cases of CRPS in the United States
    • 7.4.5. Type-specific Diagnosed Prevalent Cases of CRPS in the United States
    • 7.4.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in the United States
    • 7.4.7. Treated cases of CRPS in the United States
  • 7.5. EU-5 Epidemiology
  • 7.6. Germany
    • 7.6.1. Total Prevalent Cases of CRPS in Germany
    • 7.6.2. Total Diagnosed Prevalent cases of CRPS in Germany
    • 7.6.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Germany
    • 7.6.4. Age-specific Diagnosed Prevalent Cases of CRPS in Germany
    • 7.6.5. Type-specific Diagnosed Prevalent Cases of CRPS in Germany
    • 7.6.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Germany
    • 7.6.7. Treated cases of CRPS in Germany
  • 7.7. France
    • 7.7.1. Total Prevalent Cases of CRPS in France
    • 7.7.2. Total Diagnosed Prevalent cases of CRPS in France
    • 7.7.3. Gender-specific Diagnosed Prevalent Cases of CRPS in France
    • 7.7.4. Age-specific Diagnosed Prevalent Cases of CRPS in France
    • 7.7.5. Type-specific Diagnosed Prevalent Cases of CRPS in France
    • 7.7.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in France
    • 7.7.7. Treated cases of CRPS in France
  • 7.8. Italy
    • 7.8.1. Total Prevalent Cases of CRPS in Italy
    • 7.8.2. Total Diagnosed Prevalent cases of CRPS in Italy
    • 7.8.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Italy
    • 7.8.4. Age-specific Diagnosed Prevalent Cases of CRPS in Italy
    • 7.8.5. Type-specific Diagnosed Prevalent Cases of CRPS in Italy
    • 7.8.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Italy
    • 7.8.7. Treated cases of CRPS in Italy
  • 7.9. Spain
    • 7.9.1. Total Prevalent Cases of CRPS in Spain
    • 7.9.2. Total Diagnosed Prevalent cases of CRPS in Spain
    • 7.9.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Spain
    • 7.9.4. Age-specific Diagnosed Prevalent Cases of CRPS in Spain
    • 7.9.5. Type-specific Diagnosed Prevalent Cases of CRPS in Spain
    • 7.9.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Spain
    • 7.9.7. Treated cases of CRPS in Spain
  • 7.10. The United Kingdom
    • 7.10.1. Total Prevalent Cases of CRPS in the United Kingdom
    • 7.10.2. Total Diagnosed Prevalent cases of CRPS in the United Kingdom
    • 7.10.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
    • 7.10.4. Age-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
    • 7.10.5. Type-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
    • 7.10.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
    • 7.10.7. Treated cases of CRPS in the United Kingdom
  • 7.11. Japan Epidemiology
    • 7.11.1. Total Prevalent Cases of CRPS in Japan
    • 7.11.2. Total Diagnosed Prevalent cases of CRPS in Japan
    • 7.11.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Japan
    • 7.11.4. Age-specific Diagnosed Prevalent Cases of CRPS in Japan
    • 7.11.5. Type-specific Diagnosed Prevalent Cases of CRPS in Japan
    • 7.11.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Japan
    • 7.11.7. Treated cases of CRPS in Japan

8. Treatment and Management of CRPS

  • 8.1. Treatment Guidelines
    • 8.1.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 4th Edition - the USA
    • 8.1.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults

9. Unmet Needs

10. Patient Journey

11. Key Endpoints in CRPS Clinical Trials

12. Emerging Therapies

  • 12.1. Key Cross Competition
  • 12.2. Soticlestat (TAK-935/OV935): Ovid Therapeutics/Takeda
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
  • 12.3. BHV-5000: AstraZeneca/Biohaven Pharmaceutical
    • 12.3.1. Product Description
    • 12.3.2. Other Developmental Activities
    • 12.3.3. Clinical Development

13. CRPS: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Outlook: 7MM
  • 13.3. 7MM Market Size
    • 13.3.1. Total Market Size of CRPS in the 7MM
    • 13.3.2. Total Market size of CRPS by Therapies in the 7MM
  • 13.4. United States Market Size
    • 13.4.1. Total Market size of CRPS in the United States
  • 13.5. EU-5 Market Size
  • 13.6. Germany Market Size
    • 13.6.1. Total Market size of CRPS in Germany
  • 13.7. France Market Size
    • 13.7.1. Total Market size of CRPS in France
  • 13.8. Italy Market Size
    • 13.8.1. Total Market size of CRPS in Italy
  • 13.9. Spain Market Size
    • 13.9.1. Total Market size of CRPS in Spain
  • 13.10. United Kingdom Market Size
    • 13.10.1. Total Market size of CRPS in the United Kingdom
  • 13.11. Japan Market Size
    • 13.11.1. Total Market size of CRPS in Japan

14. Market Access and Reimbursement

15. Market Drivers

16. Market Barriers

17. Appendix

  • 17.1. Bibliography
  • 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Back to Top
전화 문의
F A Q